Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Spatial transcriptome profile of liver tissue from a patient with metabolic dysfunction-associated steatotic liver disease

ABSTRACT: Metabolic dysfunction-associated steatotic liver disease (MASLD) causes progressive liver fibrosis and hepatocellular carcinoma (HCC). By using archived fixed surgical liver tissue affected with MASLD, we performed Visium Spatial Transcriptome profiling to study spatially-resolved moelcular dysregulatons associated with the clinical phenotypes of the disease and mechanisms of liver fibrogenesis and carcinogenesis.

ORGANISM(S): Homo sapiens

PROVIDER: GSE278621 | GEO | 2026/07/22

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

RNA-seq data of primary human hepatocytes spheroids from healthy and Metabolic dysfunction associated steatotic liver disease (MASLD) donors following troglitazone treatment

Project description:Primary human hepatocytes from healthy and Metabolic dysfunction associated steatotic liver disease (MASLD) patients (6 donors each) as 3D spheroids treated with troglitazone (3 concentrations, 0.1xCmax, Cmax and 10xCmax) and vehicle for 7 h. Data for Figure 5 in connected publication.

2026-01-16 | E-MTAB-15610 | biostudies-arrayexpress

Deep proteome profiling of metabolic dysfunction-associated steatotic liver disease

Project description:Analyze human biopsies for the investigation of metabolic dysfunction-associated steatotic liver disease (MASLD). We also analyzed plasma samples for biomarker discovery. And analyzed the role of the impact of the adipose tissue on plasma proteins in relation to MASLD

2025-03-05 | PXD051911 | Pride

Single-cell RNA Sequencing Reveals the Heterogeneity of Monocyte-derived Macrophages in Liver of Metabolic Dysfunction-associated Steatotic Liver Disease

Project description:Monocyte-derived macrophages (MoMFs) orchestrate inflammation and fibrogenesis in metabolic dysfunction-associated steatotic liver disease (MASLD). However, current therapeutic strategies targeting macrophage-mediated inflammation have shown limited clinical efficacy in MASLD. Using single-cell RNA sequencing (scRNA-seq) analysis of liver-infiltrating MoMFs from MASLD mouse models, we identified seven distinct clusters (c0-c6) with unique molecular signatures. Among these, the predominant CD14+CCR2+ (c0) showed multifaceted functions in fibrosis, lipid phagocytosis, and antigen presentation beyond inflammation. We identified two distinct clusters, CCR3+ (c3) and CCR7+ (c4) MoMFs, which exhibited enhanced pro-inflammatory/oxidative stress activity and specialized antigen-presenting capacity, respectively. Pseudotime analysis revealed that the resident basal cluster (c1) could give rise to both CD14+CCR2+ (c0) and CCR7+ (c4) MoMFs during disease progression, challenging the traditional view that CCR2+ MoMFs exclusively originate from bone marrow. Notably, these MoMFs subsets and their dynamic changes during disease progression were conserved between mouse models and human MASLD samples. These findings expand our understanding of MoMFs heterogeneity and suggest new therapeutic strategies for MASLD.

2026-05-15 | GSE295950 | GEO

Untargeted proteomic analysis of simultaneously collected human liver tissue and plasma of patients with a histological diagnosis of metabolic dysfunction-associated steatotic liver disease.

Project description:The liver tissue and plasma were collected from patients when undergoing liver biopsy for a diagnosis of metabolic dysfunction-associated steatotic liver disease (MASLD), along with controls who had no histological abnormalities. The study group included seven patients with no liver histological abnormalities and 64 patients with MASLD across its spectrum, including those with metabolic dysfunction-associated steatotic hepatitis (MASH) and those with cirrhosis. The data were compared between liver tissue and plasma, across various stages of MASLD, and for the detection of biomarkers for different stages of MASLD.

2024-06-07 | MSV000094959 | MassIVE

Transcriptional profiling of liver obtained from a mouse model for metabolic dysfunction-associated steatotic liver disease

Project description:Metabolic dysfunction-associated steatotic liver disease (MASLD) is a prevalent hepatic disorder worldwide and closely associated with type 2 diabetes mellitus (T2DM). The pathogenesis of MASLD is multifaceted and its treatment options are very limited. Consequently, it is urgent to identify novel therapeutic targets and develop effective treatment strategies. RNA sequencing analysis was performed to understand the transcriptomic changes in a mouse model of MASLD.

2025-01-20 | GSE279512 | GEO

Single nucleus chromatin accessibility Profiling on the human metabolic dysfunction associated steatotic liver disease samples

Project description:Single-nucleus Assay for Transposase-Accessible Chromatin with sequencing (snATAC-seq) in human mapping of chromatin accessibility in specific cell clusters profiled alterations in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) samples compared to normal controls, providing insights into cell-type-specific epigenetic changes associated with MASLD.

2026-03-16 | GSE281367 | GEO

Transcriptomic profiles of liver biopsies in obese patients with metabolic dysfunction-associated steatotic liver disease

Project description:The molecular mechanisms underlying early-stage metabolic dysfunction-associated steatotic liver disease (MASLD) is poorly understood. This study characterized the transcriptomic alterations in obese patients with no pathology or early-stage MASLD. 94 snap-frozen liver biopsies were analyzed through high-throughput RNA sequencing. Distinct features involved in the development of hepatic steatosis and fibrosis were identified. This study also provided novel insights in mechanisms involved in the onset of fibrosis, highlighting potential therapeutic targets.

2025-12-10 | GSE281797 | GEO

Hepatic miR-93 promotes the pathogenesis of metabolic dysfunction-associated steatotic liver disease by suppressing SIRT1

Project description:The molecular mechanisms underlying the pathogenesis of metabolic dysfunction-associated steatotic liver disease (MASLD) remain largely unclear. Emerging evidence suggests that microRNAs (miRNAs) play a critical role in transcriptional regulation by targeting genes involved in MASLD and other metabolic disorders, this study aims to elucidate the role of miR-93 in lipid metabolism and its impact on MASLD progression.

2025-04-14 | GSE277560 | GEO

NSD2 aggravates metabolic dysfunction-associated steatotic liver disease progression by suppressing TFEB-mediated autophagy-lysosomal pathway

Project description:Extensive research has demonstrated that impaired autophagy contributes to the development of metabolic dysfunction-associated steatotic liver disease (MASLD). Qiao et al. identified NSD2 in the liver as a novel and essential regulator of MASLD. NSD2 epigenetically represses TFEB transcription through trimethylation of histone H4 at lysine 20 (H4K20me3), thereby impairing autophagic flux to exacerbate hepatic steatosis. In conclusion, NSD2 functions as a crucial epigenetic regulator of impaired autophagic flux in the liver, offering a novel therapeutic target for MASLD management.

2026-01-01 | GSE287554 | GEO

Liver-Targeted siRNA Therapy Reveals a Causal Role of Metabolic Dysfunction-Associated Steatotic Liver Disease in Brain Dysfunction

Project description:Metabolic-dysfunction-associated steatotic liver disease (MASLD) has traditionally been studied as a liver-centric condition. However, growing clinical and experimental evidence reveals a strong link between MASLD and cognitive impairment and sensorimotor alterations. The mechanisms underlying this liver-brain axis remain poorly defined, and whether hepatic dysfunction alone is sufficient to drive central nervous system deficits is unclear. Using diet-induced non-obese mouse models of MASLD, we performed comprehensive neurocognitive and behavioral assessments. MASLD was associated with marked alterations in social memory, sensorimotor processing, and hippocampal function, including decreased parvalbumin-positive interneurons, reduced dendritic spine density, and diminished indicators of neurogenesis in the hippocampal dentate gyrus. Then, we selectively modulated liver metabolism through a hepatocyte-targeted siRNA therapy against Cyclin M4 (CNNM4), a magnesium transporter dysregulated in MASLD, employing GalNAc-siRNA technology for targeted delivery. Notably, liver-specific intervention with siRNA-CNNM4 reversed features of impaired social memory and sensorimotor processing through recovery of hippocampal synaptogenesis and mitochondrial function pathways, alongside activation of neurogenesis-associated transcriptional programs. Our findings demonstrate that liver pathology is sufficient to drive neurobehavioral and hippocampal dysfunction in MASLD. Importantly, hepatic-specific intervention restores brain function, strongly supporting the existence of a causal and therapeutically targetable liver-brain axis. These results open new avenues for treating MASLD-associated neurological complications through liver-directed therapies.

2025-09-22 | PXD063321 | Pride

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data